Findings reveal TMEM205 promotes drug resistance and TAM/M2 polarization in triple-negative breast cancer, indicating therapeutic potential.
Transmembrane protein 205 (TMEM205) is aberrantly expressed in various tumors and is closely associated with cisplatin (DDP) resistance. However, its role in tumor progression and drug resistance in triple-negative breast cancer (TNBC) remains unclear. This study systematically investigates the regulatory function of TMEM205 in DDP-resistant TNBC and explores the underlying molecular mechanisms through a series of in vitro and in vivo experiments. Ours results demonstrate that TMEM205 promotes biological functions in TNBC cells by activating the Wnt/β-catenin signaling pathway, which subsequently induces tumor-associated macrophage (TAM)/M2 polarization, thereby promoting DDP resistance. These findings suggest that TMEM205 may serve as a potential therapeutic target for managing DDP-resistant TNBC, offering novel strategies and insights for the treatment of TNBC.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: